Matthew Durdy, Chief Executive, Cell and Gene Therapy Catapult, London, UK, describes some of the key chemistry, manufacturing and control (CMC) challenges facing the cell and gene therapy sector. He explains how the Cell and Gene Therapy Catapult works closely with companies in the UK to help them with the non-proprietary aspects of large-scale manufacturing by providing infrastructure and expertise on commercialization, manufacturing and regulation. Eight companies are currently operating from and working together in the Catapult’s large-scale GMP manufacturing center, making it the third largest cluster in the world for cell and gene therapy manufacturing. This interview took place during the Cell & Gene Meeting on the Mediterranean 2021 virtual conference.
Matthew Durdy is employed by the Cell and Gene Therapy Catapult, London, UK.